Wednesday, July 8, 2026

Drug profile · INN

revefenacin

revefenacin (REVEFENACIN) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.

FDA: approved NMPA: clinical trials
US status approved
Patents linked 10
Pipeline programs 3
News articles 0
Drug details — revefenacin
US status
approved
Class
Route
INHALATION
Patents
10
Programs
3
Data quality
0.84

Quick answer

revefenacin (REVEFENACIN) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.

Key facts

INN revefenacin
Brand REVEFENACIN
Mechanism Muscarinic acetylcholine receptor M3 antagonist
Target Muscarinic acetylcholine receptor M3
Route INHALATION
Formulation SOLUTION

Mechanism of action

Muscarinic acetylcholine receptor M3 antagonist

Primary target: Muscarinic acetylcholine receptor M3

Approval history

Authority Status Date
FDA approved
NMPA clinical trials

Pipeline programs

  1. Revefenacin Phase 3 · Theravance Biopharma Ireland · Chronic Obstructive Pulmonary Disease, COPD
  2. Revefenacin Inhalation Solution [Yupelri] Phase 2 · Theravance Biopharma Ireland · COPD
  3. Revefenacin Approved · Theravance Biopharma Ireland · Chronic Obstructive Pulmonary Disease

Related & competitor drugs

  1. ipratropium bromide Muscarinic acetylcholine receptor M3 antagonist
  2. acetylcholine chloride Muscarinic acetylcholine receptor M3 agonist
  3. aclidinium bromide Respiratory system (R03)
  4. carbachol Muscarinic acetylcholine receptor M3 agonist
  5. cyclopentolate hydrochloride Muscarinic acetylcholine receptor M3 antagonist
  6. methacholine chloride Muscarinic acetylcholine receptor M3 agonist

Related patents

  1. US 12285417

    Methods for treating chronic obstructive pulmonary disease

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12048692

    Methods for treating chronic obstructive pulmonary disease

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11858898

    Crystalline freebase forms of a biphenyl compound

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11691948

    Crystalline freebase forms of a biphenyl compound

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11484531

    Methods for treating chronic obstructive pulmonary disease

    Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11008289

    Crystalline freebase forms of a biphenyl compound

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 10550081

    Crystalline freebase forms of a biphenyl compound

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 9765028

    Crystalline freebase forms of a biphenyl compound

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 8541451

    Crystalline freebase forms of a biphenyl compound

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 7288657

    Biphenyl compounds useful as muscarinic receptor antagonists

    Expires Mon Oct 25 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is revefenacin?

revefenacin (REVEFENACIN) is a muscarinic acetylcholine receptor m3 antagonist. Route of administration: inhalation. Current US regulatory status: approved.

What is the brand name for revefenacin?

REVEFENACIN is a marketed brand name for revefenacin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of revefenacin?

revefenacin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.